GLP-1 Drugs Offer More Than Weight Loss and Glucose Control скачать в хорошем качестве

GLP-1 Drugs Offer More Than Weight Loss and Glucose Control

Dr Priya Jaisinghani discusses the benefits of GLP-1 therapy beyond glycemic control and weight management. https://www.medscape.com/viewarticle/... -TRANSCRIPT- Hi. I'm Dr Priya Jaisinghani, an endocrinologist and obesity medicine specialist. GLP-1 receptor agonists like semaglutide and tirzepatide are revolutionizing the treatment of type 2 diabetes and obesity. What many physicians may not highlight to patients is that their benefits go far beyond glycemic control and weight management. Evidence shows that these medications can reduce the risk for major adverse cardiovascular events, such as nonfatal heart attacks and strokes, which is an absolute game changer for many patients. Beyond that, GLP-1 receptor agonists have shown their ability to improve heart failure with preserved ejection fraction, slow the progression of renal disease in people living with diabetes, and alleviate knee osteoarthritis. For tirzepatide, a GIP/GLP-1 receptor agonist, research shows benefits in managing obstructive sleep apnea. Both medications show promise in addressing nonalcoholic fatty liver disease. These chronic conditions can have a profound impact on patients’ overall health and quality of life. By discussing these broader benefits during patient visits, we can help individuals see how GLP-1 receptor agonists align with their unique health goals. Whether it's improving metabolic health, reducing cardiovascular risk, or enhancing quality of life, these medications offer a truly holistic approach to care. When counseling patients, it's crucial to emphasize that GLP-1 receptor agonists are not just about weight loss or glucose control; they're about empowering patients to take charge and improve their overall health. Stay ahead and stay informed with me, Dr J. Transcript in its entirety can be found by clicking here: https://www.medscape.com/viewarticle/...